Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOSEMITE: Faricimab vs Aflibercept in Diabetic Macular Edema
jRCT2080224090Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of faricimab in diabetic macular edema (DME) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Oct 2018; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCT2080224090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224090.